The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman’s disease

BMC Pediatrics

Kazumoto Iijima⁴  Masaru Kojima⁶  Keiichiro Uehara²  Hiroshi Nagai⁷  Goichi Kageyama³  Eiryu Kyo⁵  Yasuhiro Takeshima⁴  Tomoko Yanai⁴  Takeshi Mori⁴  Nobuyuki Yamamoto⁴  Satoshi Hirase⁴  Akira Hayakawa⁴  Akihiro Yachie¹  Ikuko Kubokawa⁴ 

[1] Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan;Department of Diagnostic Pathology, Kobe University Hospital, 7-5-2 Kusunoki-Cho, Chuo-ku, Kobe 650-0017, Japan;Department of Rheumatology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-ku, Kobe 650-0017, Japan;Department of Pediatrics, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-ku, Kobe 650-0017, Japan;Department of Pediatrics, Nishiwaki Municipal Hospital, 652-1 Shimo-toda, Nishiwaki 677-0043, Japan;Department of Diagnostic and Anatomic Pathology, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan;Department of Dermatology, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-Cho, Chuo-ku, Kobe 650-0017, Japan

关键词: Soluble TNF-receptors;    Neopterin;    VEGF;    IL-6;    Tocilizumab;    Organomegaly;    Renal dysfunction;    reticulin Fibrosis of the bone marrow;    Anasarca;    Thrombocytopenia;   

Others  :  1138813
DOI  :  10.1186/1471-2431-14-139

 received in 2014-02-25, accepted in 2014-05-23,  发布年份 2014

【 摘 要 】

Background

TAFRO syndrome is a unique clinicopathologic variant of multicentric Castleman’s disease that has recently been identified in Japan. It is characterized by a constellation of symptoms: Thrombocytopenia, Anasarca, reticulin Fibrosis of the bone marrow, Renal dysfunction and Organomegaly (TAFRO). Previous reports have shown that affected patients usually respond to immunosuppressive therapy, but the disease sometimes has a fatal course. TAFRO syndrome occurs in the middle-aged and elderly and there are no prior reports of the disease in adolescents. Here we report the first adolescent case, successfully treated with anti-IL-6 receptor antibody (tocilizumab, TCZ) and monitored with serial cytokine profiles.

Case presentation

A 15-year-old Japanese boy was referred to us with fever of unknown origin. Whole body computed tomography demonstrated systemic lymphadenopathy, organomegaly and anasarca. Laboratory tests showed elevated C-reactive protein and hypoproteinemia. Bone marrow biopsy revealed a hyperplastic marrow with megakaryocytic hyperplasia and mild reticulin fibrosis. Despite methylprednisolone pulse therapy, the disease progressed markedly to respiratory distress, acute renal failure, anemia and thrombocytopenia. Serum and plasma levels of cytokines, including IL-6, vascular endothelial growth factor, neopterin and soluble tumor necrosis factor receptors I and II, were markedly elevated. Repeated weekly TCZ administration dramatically improved the patient’s symptoms and laboratory tests showed decreasing cytokine levels.

Conclusion

To our knowledge, this is the first report of TAFRO syndrome in a young patient, suggesting that this disease can occur even in adolescence. The patient was successfully treated with TCZ. During our patient’s clinical course, monitoring cytokine profiles was useful to assess the disease activity of TAFRO syndrome.

【 授权许可】

   
2014 Kubokawa et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, Kinoshita T, Masaki Y: Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop 2013, 53(1):57-61.
• [2]Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M: Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin a: a case report. J Clin Exp Hematop 2013, 53(1):95-99.
• [3]Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, Orita Y, Nakao S, Yoshino T: Atypical hyaline vascular-type castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop 2013, 53(1):87-93.
• [4]Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, Kadowaki N, Takaori-Kondo A: Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med 2013, 52(13):1503-1507.
• [5]Masaki Y, Nakajima A, Iwao H, Kurose N, Sato T, Nakamura T, Miki M, Sakai T, Kawanami T, Sawaki T, Fujita Y, Tanaka M, Fukushima T, Okazaki T, Umehara H: Japanese variant of multicentric Castleman’s disease associated with serositis and thrombocytopenia–a report of two cases: is TAFRO syndrome (Castleman- Kojima disease) a distinct clinicopathological entity? J Clin Exp Hematop 2013, 53(1):79-85.
• [6]Takai K, Nikkuni K, Shibuya H, Hashidate H: Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly. Jpn J Clin Hematol 2010, 51(5):320-325.
• [7]Bhat L, Sams HH, King LE Jr: Bullous pemphigoid associated with Castleman disease. Arch Dermatol 2001, 137(7):965-966.
• [8]Daneshpazhooh M, Moeineddin F, Kiani A, Naraghi ZS, Firooz A, Akhyani M, Chams-Davatchi C: Fatal paraneoplastic pemphigus after removal of Castleman's disease in a child. Pediatr Dermatol 2012, 29(5):656-657.
• [9]Nikolskaia OV, Nousari CH, Anhalt GJ: Paraneoplastic pemphigus in association with Castleman’s disease. Br J Dermatol 2003, 149(6):1143-1151.
• [10]Kojima M, Nakamura S, Nishikawa M, Itoh H, Miyawaki S, Masawa N: Idiopathic multicentric Castleman’s disease. A clinicopathologic and immunohistochemical study of five cases. Pathol Res Pract 2005, 201(4):325-332.
• [11]van Rhee F, Stone K, Szmania S, Barlogie B, Singh Z: Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010, 8(7):486-498.
• [12]Cesarman E, Knowles DM: The role of Kaposi’s sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Semin Cancer Biol 1999, 9(3):165-174.
• [13]Kojima M, Nakamura N, Tsukamoto N, Otuski Y, Shimizu K, Itoh H, Kobayashi S, Kobayashi H, Murase T, Masawa N, Kashimura M, Nakamura S: Clinical implications of idiopathic multicentric castleman disease among Japanese: a report of 28 cases. Int J Surg Pathol 2008, 16(4):391-398.
• [14]Kojima M, Nakamura N, Tsukamoto N, Yokohama A, Itoh H, Kobayashi S, Kashimura M, Masawa N, Nakamura S: Multicentric Castleman’s disease representing effusion at initial clinical presentation: clinicopathological study of seven cases. Lupus 2011, 20(1):44-50.
• [15]Komatsuda A, Wakui H, Togashi M, Sawada K: IgA nephropathy associated with Castleman disease with cutaneous involvement. Am J Med Sci 2010, 339(5):486-490.
• [16]Xu D, Lv J, Dong Y, Wang S, Su T, Zhou F, Zou W, Zhao M, Zhang H: Renal involvement in a large cohort of Chinese patients with Castleman disease. Nephrol Dial Transplant 2012, 27(Suppl 3):iii119-iii125.
• [17]Baserga M, Rosin M, Schoen M, Young G: Multifocal Castleman disease in pediatrics: case report. J Pediatr Hematol Oncol 2005, 27(12):666-669.